Berber Ilhami, Erkurt Mehmet Ali, Kuku Irfan, Kaya Emin, Bag Harika Gozukara, Nizam Ilknur, Koroglu Mustafa, Ozgul Mustafa
Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey.
Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey.
Transfus Apher Sci. 2016 Feb;54(1):48-52. doi: 10.1016/j.transci.2016.01.012. Epub 2016 Jan 12.
This study aimed to evaluate the efficiency of DHAP regimen plus filgrastim for mobilization of stem cells in patients with recurrent and/or refractory lymphoma. Thirty-four patients who took DHAP as salvage therapy prior to autologous stem cell transplantation were included. After chemotherapies, 2 cycles of DHAP plus filgrastim were administered to the patients. Stem cells from 32 patients (94%) were collected on median 11th day (8-12), and the median collected CD34(+) cell dose was 9.7 × 10(6)/kg (range 3.8-41.6). DHAP plus filgrastim was found to be an effective chemotherapy regimen in mobilizing CD34(+) stem cells into the peripheral.
本研究旨在评估DHAP方案联合非格司亭用于动员复发和/或难治性淋巴瘤患者干细胞的有效性。纳入了34例在自体干细胞移植前接受DHAP作为挽救治疗的患者。化疗后，对患者给予2个周期的DHAP联合非格司亭治疗。32例患者（94%）的干细胞在第11天（8 - 12天）中位数时采集，采集的CD34(+)细胞剂量中位数为9.7×10(6)/kg（范围3.8 - 41.6）。发现DHAP联合非格司亭是一种将CD34(+)干细胞动员至外周血的有效化疗方案。
